VBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference

Press/Media: Press / Media

PeriodSep 17 2015

Media coverage

29

Media coverage

  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletReuters
    CountryUnited Kingdom
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletYahoo! Finance
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletPharmiWeb
    CountryUnited Kingdom
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletTown Hall
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletVision Monday
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletMarketplace
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletIndustrial Info Financials
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletCEOWorld Magazine
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletRCL Advisors
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletWall Street Business Network
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletCrawford Financial Planning
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletMarket Pulse Navigator
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletMoneyShow.com
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletFat Pitch Financials
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletReliance Trust
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletFranklin Credit Management Corporation
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletBioSpace
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletA.M. Best
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletSearchBug
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletYahoo! 7 Finance
    CountryAustralia
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outlet4 Traders
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletTamar Securities
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletFinancial Content
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletVirtual Strategy Magazine
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletU-T San Diego
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletGood Day Sacramento
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletAsk.com
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletGlobeNewswire
    CountryUnited States
    Date9/17/15
    PersonsAndrew Brenner
  • TitleVBL Therapeutics to Present Complete Phase 2 Data on VB-111 in Combination With Bevacizumab in Recurrent GBM at the European Cancer Conference
    Media name/outletBizWire Express
    CountryIndia
    Date9/17/15
    PersonsAndrew Brenner